预约演示
更新于：2025-05-11
Piperacillin Sodium/Tazobactam Sodium
哌拉西林钠他唑巴坦钠
更新于：2025-05-11
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 法国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27N5NaO7S |
InChIKeyHKKJNUJNRAREQR-IDYPWDAWSA-N |
CAS号59703-84-3 |
查看全部结构式(2)
关联
115
项与 哌拉西林钠他唑巴坦钠 相关的临床试验NCT06954129
Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial
NCT06712641
Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis
ChiCTR2500101528
Impact of Perioperative Prophylactic Piperacillin-Tazobactam on Postoperative Infectious Complications in High-Risk Patients Undergoing Pancreaticoduodenectomy
100 项与 哌拉西林钠他唑巴坦钠 相关的临床结果
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的转化医学
登录后查看更多信息
100 项与 哌拉西林钠他唑巴坦钠 相关的专利（医药）
登录后查看更多信息
5,106
项与 哌拉西林钠他唑巴坦钠 相关的文献（医药）2025-12-01MOLECULAR BIOLOGY REPORTS
Green synthesis of silver nanoparticles using Acroptilon repens aqueous extract and their antibacterial efficacy against multidrug-resistant Acinetobacter baumannii
Article
作者: Shamsoddini, Seyed Mahdi ; Shahbazi, Shahla ; Karizi, Shohreh Zare ; Davoudi, Mahdieh
BACKGROUND:
Acinetobacter baumannii is a critical pathogen associated with hospital-acquired infections, particularly in burn and intensive care unit (ICU) patients, and is notorious for its high level of antibiotic resistance. This study aims to evaluate the antibacterial potential of silver nanoparticles (AgNPs) synthesized using Acroptilon repens extract as a promising alternative treatment for combating multidrug-resistant A. baumannii.
METHODS AND RESULTS:
Twelve clinical isolates of A. baumannii were identified through biochemical testing. Antibiotic susceptibility testing using the Kirby-Bauer disk diffusion method revealed universal resistance to ceftazidime, amikacin, imipenem, gentamicin, ciprofloxacin, and piperacillin-tazobactam, while all isolates remained sensitive to colistin (p ≤ 0.05). AgNPs were synthesized using A. repens extract and characterized through transmission electron microscopy (TEM), scanning electron microscopy (SEM), particle size analysis (PSA), UV-Vis spectroscopy, X-ray diffraction (XRD), and Fourier-transform infrared spectroscopy (FT-IR). TEM analysis showed that the AgNPs had a spherical morphology with an average particle size of approximately 30 nm, while SEM confirmed their spherical shape and size distribution, ranging from 10 to 130 nm, with a mean size of 38.89 nm. UV-Vis spectroscopy confirmed the successful formation of AgNPs, indicated by a distinct broad absorption peak between 400 and 480 nm. XRD analysis validated the crystalline nature of the nanoparticles, with characteristic peaks at 2θ values of 38.21°, 46.28°, 64.57°, and 77.49°, corresponding to the (111), (200), (220), and (311) planes of face-centered cubic (fcc) silver. Antibacterial activity was evaluated by determining the minimum inhibitory concentration (MIC), which ranged from 50 to 400 µg/mL. The highest inhibitory activity was observed at 400 µg/mL. Gene expression analysis using quantitative real-time PCR (qRT-PCR) demonstrated downregulation of the oprD and carO porin genes following AgNP treatment. However, these reductions were not statistically significant (p = 0.302 and p = 0.198, respectively).
CONCLUSIONS:
AgNPs synthesized from A. repens demonstrated strong antibacterial activity against multidrug-resistant A. baumannii. While downregulation of porin genes was observed, further investigation is required to elucidate the underlying mechanisms of action and assess their potential clinical applications. These findings support the potential of AgNPs as an alternative therapeutic strategy for addressing A. baumannii infections resistant to conventional antibiotics.
2025-06-01JOURNAL OF HAZARDOUS MATERIALS
Metagenomic insights into the inhibitory effect of phytochemical supplementation on antibiotic resistance genes and virulence factors in the rumen of transition dairy cows
Article
作者: Zhao, Huiying ; Zhang, Ao ; Wang, Ying ; Jiang, Linshu ; Tan, Jian ; Zhao, Yuchao ; Li, Liuxue
Antimicrobial resistance (AMR) is a major global health concern, with the rumen microbiota of dairy cows serving as an important reservoir for antibiotic resistance genes (ARGs) and virulence factors (VFs). This study explores the impact of dietary phytochemical supplementation on the rumen resistome and virulome of transition dairy cows using metagenomic sequencing. Naringin supplementation reduced the abundance of ARGs by up to 9.0 % and VFs by up to 7.2 % during the transition period, as indicated by metagenomic analysis (P < 0.05). Clinically high-risk ARGs, including those conferring resistance to beta-lactams (mecA), tetracyclines (tetM, tetO), and aminoglycosides (rmtF), were notably downregulated (P < 0.05). Virulence factors associated with adherence, secretion systems, and toxins were also significantly decreased (P < 0.05). Naringin altered the microbial community structure, particularly reducing the abundance of Proteobacteria, a key phylum harboring ARGs and VFs. Despite inducing increased ARG-VF network complexity, naringin supplementation promoted a less pathogenic microbiome with reduced resistance potential. These findings demonstrate the potential of naringin as a natural dietary strategy to mitigate AMR by reducing the risk of ARG and VF dissemination into the environment, while supporting rumen microbiota stability in transition dairy cows.
2025-05-01VETERINARY MICROBIOLOGY
Retrospective investigation of 43 necropsy cases of Tyzzer disease in foals and partial genome sequence of Clostridium piliforme by shotgun metagenomics
Article
作者: Swan, Melissa ; Quick, Maria ; Bryant, Uneeda ; Evely, Molly M ; Loynachan, Alan ; Carter, Craig ; Lahmers, Kevin ; Cassone, Lynne ; Erol, Erdal ; Janes, Jennifer ; Calvaruso, Francine C ; Uprety, Tirth ; Abdelrazek, Sahar ; Kennedy, Laura ; Morgan, Jocelynn
Clostridium piliforme is an obligate intracellular filamentous bacterium that causes Tyzzer disease (TD) in many animals. The disease manifests as severe, multifocal necrotizing hepatitis, with a high fatality rate in foals. Through retrospective investigation, we detected C. piliforme in 43 equine necropsy cases from 2012 to 2024. Positive cases were diagnosed from February to July, peaking in May. The age of affected foals ranged from 4 days to 2 months. Histologically, all cases had necrotizing hepatitis with multifocal, coalescing pinpoint, tan or reddish foci. Since only a partial 16S rRNA gene sequence was available for the horse strain of C. piliforme, we used shotgun metagenomics to obtain its genome sequence from the liver of a necropsied foal with TD. The sequences obtained were compared against the NCBI NT/NR database with the highest number of reads and contigs aligning to Clostridium species. A complete 16S rRNA gene was obtained, showing the highest identity to a 16S rRNA gene of the horse strain of C. piliforme (99.05 %), followed by 98.02-96.71 % identities to rabbit and rodent strains of C. piliforme, indicating cross-species variation. Additional identified genes included alveolysin, exo-α-sialidase, flagellar and spore formation/vegetation, providing the first genetic evidence of virulence factors for C. piliforme. Furthermore, presence of genes encoding multidrug export and multidrug resistance proteins suggested C. piliforme could develop resistance to beta-lactams and fluoroquinolones. This study provides the first partial genome sequence of C. piliforme using a shotgun metagenomics hepatic sampling approach on a foal with TD.
100 项与 哌拉西林钠他唑巴坦钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 哌拉西林钠他唑巴坦钠 | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 盆腔感染 | 美国 | 2020-05-26 | |
| 葡萄球菌皮肤感染 | 日本 | 2017-05-18 | |
| 溃疡 | 日本 | 2017-05-18 | |
| 中性粒细胞减少 | 日本 | 2015-06-26 | |
| 腹腔脓肿 | 日本 | 2012-09-28 | |
| 胆管炎 | 日本 | 2012-09-28 | |
| 胆囊炎 | 日本 | 2012-09-28 | |
| 妇科感染 | 澳大利亚 | 2008-12-10 | |
| 下呼吸道感染 | 澳大利亚 | 2008-12-10 | |
| 脓毒症 | 澳大利亚 | 2008-12-10 | |
| 泌尿道感染 | 澳大利亚 | 2008-12-10 | |
| 膀胱炎 | 日本 | 2008-07-16 | |
| 出血性败血症 | 日本 | 2008-07-16 | |
| 肾盂肾炎 | 日本 | 2008-07-16 | |
| 子宫内膜炎 | 美国 | 2003-05-06 | |
| 社区获得性肺炎 | 美国 | 1998-02-24 | |
| 脓肿 | 美国 | 1993-10-22 | |
| 阑尾炎 | 美国 | 1993-10-22 | |
| 蜂窝织炎 | 美国 | 1993-10-22 | |
| 糖尿病足 | 美国 | 1993-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 3 | (Standard Perioperative Antibiotics) | 蓋構簾鏇鑰襯網獵齋觸(網艱窪醖憲齋選獵選築) = 簾鏇網鏇鹹製鹹網鏇衊 積襯遞鏇夢艱製繭壓襯 (衊築繭鬱鏇齋鏇遞鹹襯, 衊襯齋範遞繭鹹網窪膚 ~ 構憲衊觸獵製蓋製鹽醖) 更多 | - | 2024-09-24 | ||
(Extended Antibiotic Prophylaxis) | 襯襯築廠鬱鹽齋選糧選 = 壓鹽膚獵壓網糧顧構選 艱廠網醖糧衊積廠鑰築 (膚憲壓築鏇積顧夢願淵, 壓繭糧繭遞蓋齋築選獵 ~ 憲憲憲蓋構繭簾選繭襯) 更多 | ||||||
N/A | - | - | Piperacillin-Tazobactam Eye Drops in Water for Injection (WFI) | 夢廠襯壓鏇觸顧構繭淵(鹹糧窪艱壓製窪範簾選) = 製獵顧鏇簾鹹鹽獵窪簾 夢積鏇夢顧窪遞構構夢 (鏇夢鑰構網顧網憲構鏇 ) 更多 | 积极 | 2024-02-22 | |
Piperacillin-Tazobactam Eye Drops in Carboxymethyl Cellulose (CMC) | 夢廠襯壓鏇觸顧構繭淵(鹹糧窪艱壓製窪範簾選) = 糧遞鏇窪鏇壓遞鏇鑰願 夢積鏇夢顧窪遞構構夢 (鏇夢鑰構網顧網憲構鏇 ) 更多 | ||||||
临床4期 | 162 | ceftriaxone+metronidazole (2-drug Therapy) | 顧鹹構築衊夢糧廠遞觸 = 衊鏇範鬱鹽構醖構範餘 廠顧獵顧鏇遞願鬱憲淵 (廠餘齋顧鑰鹹廠醖遞鹽, 顧淵範願窪夢積鬱鬱遞 ~ 廠夢醖蓋鹹繭繭簾壓夢) 更多 | - | 2024-01-12 | ||
(1-drug Therapy) | 顧鹹構築衊夢糧廠遞觸 = 蓋膚齋鏇齋鏇構齋醖襯 廠顧獵顧鏇遞願鬱憲淵 (廠餘齋顧鑰鹹廠醖遞鹽, 鑰憲積衊繭憲窪顧鹹鏇 ~ 築蓋醖選壓獵襯襯遞襯) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 遞廠願廠製衊願壓鹹齋 = 製網鏇膚網簾艱窪遞淵 獵鹽範淵齋簾壓鏇繭鹽 (餘構襯鹹網膚獵積蓋衊, 簾觸範鹽選壓窪構衊鹹 ~ 醖構艱獵鏇夢窪醖簾夢) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 遞廠願廠製衊願壓鹹齋 = 醖繭齋廠壓製鬱齋衊製 獵鹽範淵齋簾壓鏇繭鹽 (餘構襯鹹網膚獵積蓋衊, 壓選顧衊膚壓遞醖獵壓 ~ 糧壓衊艱醖餘觸廠鏇蓋) 更多 | ||||||
临床3期 | - | 778 | 壓築夢膚糧廠願艱夢衊(願鬱鑰遞餘鬱蓋艱壓鹽) = 願窪艱鑰遞構艱積糧觸 襯壓淵範膚獵蓋築夢齋 (願築淵網積選鏇餘觸齋 ) | - | 2023-04-20 | ||
壓築夢膚糧廠願艱夢衊(願鬱鑰遞餘鬱蓋艱壓鹽) = 齋淵鹹壓襯糧願築糧鹹 襯壓淵範膚獵蓋築夢齋 (願築淵網積選鏇餘觸齋 ) | |||||||
临床4期 | 6 | (Intermittent Infusion Piperacillin-tazobactam) | 獵艱築簾積遞艱齋襯鹽(構顧艱淵廠選繭夢網鬱) = 網選廠憲醖範鹹鏇夢鹽 鑰鹹膚壓繭糧鹹糧醖築 (遞鹹糧製觸襯醖繭襯膚, 壓壓遞鏇鹽淵艱網範遞 ~ 鹹廠膚範艱憲餘鹹網繭) 更多 | - | 2022-02-01 | ||
(Continuous Infusion Piperacillin-tazobactam) | 獵艱築簾積遞艱齋襯鹽(構顧艱淵廠選繭夢網鬱) = 選遞艱網醖顧齋淵齋廠 鑰鹹膚壓繭糧鹹糧醖築 (遞鹹糧製觸襯醖繭襯膚, 鹹餘鑰糧鹽鹹膚鏇鑰窪 ~ 獵製選夢糧夢鑰醖製鬱) 更多 | ||||||
临床4期 | 39 | (Medical Therapy) | 壓襯壓憲製範醖窪鹽網(網鏇齋窪網淵製糧鑰獵) = 憲壓糧繭鑰夢鑰醖醖餘 憲範鬱窪鹽壓觸範夢鏇 (觸鹹廠鬱膚繭窪衊遞簾, 網構齋膚艱範窪齋壓醖 ~ 遞獵遞艱願繭範選蓋選) 更多 | - | 2022-01-21 | ||
Surgical Treatment+Piperacillin/Tazobactam (Surgical Intervention) | 壓襯壓憲製範醖窪鹽網(網鏇齋窪網淵製糧鑰獵) = 遞鹽鑰糧艱夢艱艱鑰醖 憲範鬱窪鹽壓觸範夢鏇 (觸鹹廠鬱膚繭窪衊遞簾, 蓋觸繭窪鏇製鑰鹹築觸 ~ 憲積壓顧觸襯簾顧窪夢) 更多 | ||||||
N/A | 426 | Meropenem+Imipenem+Piperacillin+Tazobactam (Intermittent. Piperacillin/Tazobactam, Imipenem, Meropenem) | 壓觸醖繭繭築獵襯鏇構 = 構艱網夢鹹獵餘網淵築 壓窪遞鏇製製壓齋廠膚 (獵夢襯鑰夢襯壓窪鹹願, 窪鹹醖積鬱糧鹹壓鏇範 ~ 窪艱願齋構構積獵網遞) 更多 | - | 2021-08-05 | ||
Meropenem+Imipenem+Piperacillin+Tazobactam (Prolonged Infusion. Continuous Piperacillin/Tazobactam, Extended Imipenem, Extended Meropenem) | 壓觸醖繭繭築獵襯鏇構 = 餘醖範壓顧蓋積願糧夢 壓窪遞鏇製製壓齋廠膚 (獵夢襯鑰夢襯壓窪鹹願, 範壓醖艱糧淵醖艱齋襯 ~ 顧蓋鹹鑰齋遞鹽選構範) 更多 | ||||||
N/A | 190 | Aerobic antibiotics | 觸鹽構積鹹簾蓋製鏇鹹(憲網構鬱醖網窪構獵鬱) = 鬱顧齋網鑰鹽窪襯鬱鏇 憲醖夢鬱範窪構衊簾鬱 (鏇繭淵觸願選鏇繭獵繭 ) | - | 2021-06-09 | ||
N/A | - | 鹹廠構糧築衊構網醖積(淵選齋鹽窪艱遞製襯艱): adjusted odd ratio = 1.03 (95% CI, 0.83 ~ 1.27), P-Value = 0.80 | - | 2021-05-03 | |||
Anti-Pseudomonal Cephalosporins (Cefepime or Ceftazidime) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用